1Chertow G M;Dillon M A;Amin N.Sevelamer with and without calcium and vitamin D:observations from a long-term open-label clinical trial,2000(03). 被引量：1
2Slatopolsky E A;Burke S K;Dillon M A.RenaGel,a nonabsorbed calcium-and aluminum-free phosphate binder,lowers serum phosphorus and parathyroid hormone.The RenaGel Study Group[J],1999(01). 被引量：1
3Silver J;Kilav R;Sela-Brown A.Molecular mechanisms of secondary hyperparathyroidism,2000(07). 被引量：1
4Almaden Y;Hernandez A;Torregrosa V.High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro,1998(10). 被引量：1
5Roussanne M C;Lieberherr M;Souberbielle J C.Human parathyroid cell proliferation in response to calcium,NPS R-467,calcitriol and phosphate[J],2001(07). 被引量：1
6Emmett M;Sirmon M D;Kirkpatrick W G.Calcium acetate control of serum phosphorus in hemodialysis patients,1991(05). 被引量：2
7Savica V;Calò L A;Monardo P.Phosphate binders and management of hyperphosphataemia in end-stage renal disease[J],2006(08). 被引量：1
2Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med, 2006, 354:131-140. 被引量：1
3Cui TG, Hou FF, Chen XM, et al. A Multi-center controlled clinical trial of leflunomide treating proliferative lupus nephritis. J Am Soc Nephrol, 2004, 15:53A. 被引量：1
4Chen X, Qiu Q, Tang L, et al. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.Nephrol Dial Transplant, 2004, 19: 852-857. 被引量：1
5Gu Y, Ding F, Chen N, et al. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and muhicenter study. Ren Fail,2005, 27: 205-212. 被引量：1
6Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol, 2006, 17:2937-2944. 被引量：1
7Xin G, Wang M, Jiao LL, et al. Protein-to-creatinine ratio in spot urine samples as a predictor of quantitation of proteinuria. Clin Chim Acta, 2004, 350:35-39. 被引量：1
8Strippoli GF, Craig JC, Schena FP. The number, quality,and coverage of randomized controlled trials in nephrology. JAm Soc Nephrol, 2004, 15: 411-419. 被引量：1
9Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis, 2004, 43:197 -208. 被引量：1
10Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet, 2005, 366(9502):2026-2033. 被引量：1
8Block GA,Port FK. Re-evaluation of risks associaed with hyperphos phafemia and hyperparathyroidism in dialysis patients:recommen dations for a change in inanayement[J]. Am Kidney Dis,2000,35:1226- 1237. 被引量：1
9Cannata-Andia JB,Rodriguez-Garc.fa M. Hyperpho sphatamia as a card iovas cular risk facfor-how to manage the problem[J]. Nephrnl Dial transplant, 2002,17 (Suppl) : 16-19. 被引量：1
